Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.

“After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks,” said Kenneth Galbraith, Chair and CEO of Zymeworks. “She brings more than 20 years of public company biotech experience with a proven track record of guiding strategy, finance, operations, and governance through multiple phases of growth, planning and executing successful financial strategies. Ms. Patterson has the financial leadership qualities to support Zymeworks as we continue to make progress in achieving our ‘5 by 5’ goal of having five novel antibody-drug conjugates or novel T cell engagers in clinical studies by 2026, and progress product candidates from our ADVANCE R&D programs into clinical studies by 2027 and beyond.”

“I am very pleased to be joining Zymeworks as the Company plans for many important milestones in the months and years ahead. I look forward to working collaboratively with the experienced leadership team in maximizing the value of the rapidly expanding pipeline and addressing many critical areas of unmet medical needs for patients with difficult-to-treat cancers and other serious diseases,” said Ms. Patterson.

Prior to joining Zymeworks, Ms. Patterson served as Chief Financial and Business Officer at Tenaya Therapeutics where she led corporate finance, investor relations, corporate communications, strategy and business development teams as well as other operational functions. She previously held leadership positions at Adverum Biotechnologies including Chief Financial Officer, President, Chief Executive Officer and Director. She also has held senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron. Earlier in her career she worked in the audit practice of KPMG.

Ms. Patterson currently serves on the board of directors of Nkarta, Inc. and Oxford Biomedica, both publicly-held companies. She earned a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).

Ms. Patterson’s appointment builds on the Company’s continued focus on strengthening its leadership in the biopharmaceutical industry and expanding its pipeline of pharmaceutical candidates with the potential to make a significant difference in the lives of patients around the world with difficult-to-treat cancers and other diseases. She will be responsible for assisting with the development of Zymeworks’ long-term financial strategy, providing leadership surrounding financing and capital strategies and supporting strategic business decisions. She will be based in the new Zymeworks’ location in Redwood City, California.

About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Ms. Patterson’s anticipated appointment date; Ms. Patterson’s expected contributions to Zymeworks’ strategic goals; potential therapeutic effects and commercial potential of zanidatamab and Zymeworks’ other product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com


Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

THỦ THUẬT HAY

Các tính năng hấp dẫn của ứng dụng Gmail cho iPhone

Tuy nhiên nếu không thường xuyên cập nhật bạn sẽ không nhận ra những thay đổi thú vị qua từng lần nâng cấp phiên bản Gmail. Hãy theo dõi bài viết này để nhanh chóng trang bị cho mình những tính năng tuyệt vời này để sử

5 món đồ công nghệ không thể thiếu trong dịch COVID 19

NHỮNG THIẾT BỊ CÔNG NGHỆ KHÔNG THỂ THIẾU TRONG MÙA COVID 19 ( PHẦN 1) 1. Điện thoại Vào thời điểm mà mọi người đều có xu hướng ở trong nhà sinh hoạt nhằm phòng tránh dịch Covid, thì một chiếc điện thoại sẽ giúp bạn

Lỡ làm mất thanh Taskbar và đây là cách khắc phục

Thanh công cụ hay còn gọi là Taskbar trên máy tính được biết đến là một trong những tính năng quan trọng của hệ điều hành Windows được nhiều người dùng nhất. Thông qua đó, hệ điều hành này sẽ cung cấp một tính năng đặc

Yahoo Weather - ứng dụng theo dõi tình hình mưa bão tốt nhất trên Android

Cơn bão số 3 đang đổ bộ vào các tỉnh miền Bắc nước ta, để cập nhật tình hình thời tiết mọi lúc mọi nơi, hãy cài ngay ứng dụng theo dõi thời tiết Yahoo Weather

Hướng dẫn tắt âm thanh thông báo Windows 10

Hệ điều hành Windows 10 mang tới cho người dùng những tính năng mới, nâng cấp hơn rất nhiều so với những phiên bản trước. Trong đó phải kể đến trình thông báo thông minh trên. Tuy nhiên, một số người chỉ cần hiện popup

ĐÁNH GIÁ NHANH

Review chi tiết điện thoại Nokia C12 Pro: Có thực sự “Đáng” mua?

Nokia C12 Pro là một trong những sản phẩm mới nhất của hãng này. Với thiết kế đẹp và tính năng tốt, đây có thể là một lựa chọn tuyệt vời cho những người đang tìm kiếm một chiếc điện thoại mới. Tuy nhiên, trước khi

Rolls-Royce Phantom 2018: Liệu có phải phẩm dành cho các tài xế ngồi sau vô lăng?

Sau cánh cửa của Rolls-Royce Phantom thế hệ mới, mọi căng thẳng và phiền não của bạn sẽ được thổi bay bởi sự yên tĩnh, thoải mái và cảm giác thư thái bên trong chiếc sedan sang trọng bậc nhất thế giới. Đúng vậy,

[Review] iPad Pro 10.5 + Smart Keyboard đã làm mình muốn rời xa MacBook Pro

Trong bài này mình sẽ đánh giá chung hai món: iPad Pro 10.5 và bàn phím Apple Smart Keyboard. Hai món này hợp lại sẽ giải quyết được hầu hết các nhu cầu cơ bản của bạn trên máy tính.